Marie Bhatt

Marie Bhatt has advanced understanding and treatment of peripheral T-cell lymphomas, a heterogeneous group of rare and aggressive lymphoid malignancies with generally poor prognosis. Her research has characterized molecular subtypes of PTCL including angioimmunoblastic T-cell lymphoma driven by TET2, IDH2, and RHOA mutations, identifying therapeutic vulnerabilities in these tumors. She has contributed to clinical investigation of novel agents for PTCL including romidepsin, pralatrexate, belinostat, and brentuximab vedotin in CD30-positive T-cell lymphomas, characterizing response rates and durability. Her translational work on epigenetic dysregulation in PTCL and the role of IDH2 mutations in angioimmunoblastic T-cell lymphoma has explored enasidenib as a targeted therapeutic strategy in IDH2-mutated AITL.